ADDvise Group AB (publ) publishes updated preliminary Pro-forma financials for the ongoing acquisition- Regulatory notice

28-01-2019   Regulatory press release

Updated financials

ADDvise has prepared updated preliminary financials to clarify the impact of ADDvise's latest acquisitions on ADDvise's financials, as well as the ongoing acquisition of the previously mentioned Finnish medtech company the (“Company”) expected effect on the financials. ADDvise preliminary full year 2018 (“Prel FY 18”) financials correspond to a net sales growth of 17.7 percent and an EBITDA growth of 18.7 percent compared to fiscal year of 2017. Proforma Prel FY 18 compared to ADDvise Prel FY 18 corresponds to a net sales growth of 25.2 percent and an EBITDA growth of 47.5 percent. The following table of updated financials has not been revised or reviewed by the company's auditor. The table sets forth ADDvise Group’s updated preliminary financials, The Company’s preliminary financials and a merger of the two.

Proforma*** Company** ADDvise* ADDvise Full Year
 MSEK Prel. FY 18 Prel. FY 18 Prel. FY 18 1 Jan 2017 – 31 Dec 2017
Net Sales 353,66  71,26  282,4  239.9
EBITDA before acquisition costs 27,14  8,74  18,4  15.5
EBITDA 26,04  8,74  17,3  12.1
EBIT 19,62  8,02  11,6  7.6
EBT 6,26  7,96  -1,7  -10.6
EBITDA before acquisition costs margin 7,3%  12,8%  6,5%  6.50%
EBITDA margin 5,9%  12,8%  6,1%  5.10%
EBIT margin 4,3%  11,8%  4,1%  3.20%
Net sales growth 25,2%  10,4%  17,7%  22.80%

* Preliminary full year financials for ADDvise Group during the period 1 Jan 2018 – 31 Dec 2018.

** Preliminary full year financials for The Company during the period 1 Jan 2018 – 31 Dec 2018, converted from Euro at a rate of 1 EUR = 10.31 SEK.

*** Proforma is the sum of the preliminary financials for ADDvise Group and The Company.

The numbers are preliminary, and the fourth quarter report will be released February 21st, 2019

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71 

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on January 28th 2019, 13:15 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50,, is the Company's Certified Adviser. Additional information is available at

Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected


The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million


ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million


ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…